

References

Kava

- Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997. **1**
- Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998. **2**
- Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998. **19**
- Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Int Med 1998;158:2200-11.. [View abstract](#). **21**
- Welihinda J, et al. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 1986;17:277-82. [View abstract](#). **35**
- Strahl S, Ehret V, Dahm HH, Maier KP. [Necrotizing hepatitis after taking herbal medication]. Dtsch Med Wochenschr 1998;123:1410-4. [View abstract](#). **390**
- Spillane PK, et al. Neurological manifestations of kava intoxication. Med J Aust 1997;167:172-3. [View abstract](#). **534**
- Swensen JN. Man convicted of driving under the influence of kava. Salt Lake City, UT: Deseret News, 1996. **535**
- Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996;125:940-1. [View abstract](#). **536**
- Singh YN, Blumenthal M. Kava an overview. HerbalGram 1997;39:33-44, 46-55. **782**
- Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19. **1740**
- Woelk H, Kapoula O, Lehl S, et al. [Comparison of kava special extract WS 1490 and benzodiazepines in patients with anxiety]. Z Allg Med 1993;69:271-7. **2092**
- Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000;20:84-9. [View abstract](#). **2093**
- Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997;30:1-5. [View abstract](#). **2094**
- Lehmann E, Kinzler E, Friedemann J. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - a double-blind placebo-controlled study of four weeks treatment. Phytomedicine 1996;3:113-9. [View abstract](#). **2095**
- Warnecke G. [Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava extract WS 1490]. Fortschr Med 1991;109:119-22. [View abstract](#). **2096**
- Heinze HJ, Munthe TF, Steitz J, Matzke M. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopsychiatry 1994;27:224-30. [View abstract](#). **2097**

- 2098**
- Munte TF, Heinze HJ, Matzke M, Steitz J. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. *Neuropsychobiology* 1993;27:46-53. [View abstract.](#)
- 2500**
- Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). *Pharmacopsychiatry* 1998;31:187-92. [View abstract.](#)
- 2501**
- Gleitz J, Beile A, Wilkens P, et al. Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets. *Planta Med* 1997;63:27-30. [View abstract.](#)
- 4032**
- Wheatley D. Stress-induced insomnia treated with kava and valerian: singly and in combination. *Hum Psychopharmacol* 2001;16:353-6. [View abstract.](#)
- 4037**
- Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. *Psychopharmacology* 1994;116:469-74. [View abstract.](#)
- 4038**
- Davies LP, Drew CA, Duffield P, et al. Kava Pyrones and Resin: Studies on GABA-A, GABA-B, and Benzodiazepine Binding Sites in Rodent Brain. *Pharmacol Toxicol* 1992;71:120-6. [View abstract.](#)
- 4055**
- Schelosky L, Raffaup C, Jendroska K, Poewe W. Kava and dopamine antagonism. *J Neurol Neurosurg Psychiatry* 1995;58:639-40. [View abstract.](#)
- 6002**
- Fetrow CW, Avila JR. *Professional's Handbook of Complementary & Alternative Medicines*. 1st ed. Springhouse, PA: Springhouse Corp., 1999.
- 6240**
- Norton SA, Ruze P. Kava dermatopathy. *J Am Acad Dermatol* 1994;31:89-97. [View abstract.](#)
- 6401**
- Pizzorno JE, Murray MT, eds. *Textbook of Natural Medicine*. 2nd ed. Edinburgh:Churchill Livingstone, 1999.
- 6402**
- Mathews JD, Riley MD, Fejo L, et al. Effects of heavy usage of kava on physical health: Summary of a pilot survey in an aboriginal community. *Med J Aust* 1988;148:548-55. [View abstract.](#)
- 7024**
- Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. *BMJ* 2001;322:139. [View abstract.](#)
- 7068**
- Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity [letter]. *Ann Intern Med* 2001;135:68-9. [View abstract.](#)
- 7086**
- Liver Toxicity With Kava. *Pharmacist's Letter/Prescriber's Letter*. January 2001.
- 7096**
- Consultation letter MLX 286: Proposals to prohibit the herbal ingredient Kava-Kava (Piper methysticum) in unlicensed medicines. Medicines Control Agency, United Kingdom, July 19, 2002.
- 7325**
- Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. *Psychopharmacology (Berl)* 2001;157:277-83. [View abstract.](#)
- 7727**
- Meseguer E, Taboada R, Sanchez V, et al. Life-threatening parkinsonism induced by kava-kava. *Mov Disord* 2002;17:195-6. [View abstract.](#)
- 7728**

- Ruze P. Kava-induced dermopathy: a niacin deficiency? *Lancet* 1990;335:1442-5. [View abstract.](#) **8175**
- Steiner GG. The correlation between cancer incidence and kava consumption. *Hawaii Med J* 2000;59:420-2. [View abstract.](#) **8413**
- Wu D, Yu L, Nair MG, et al. Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from *Piper methysticum* (kava kava) roots. *Phytomedicine* 2002;9:41-7. [View abstract.](#) **8414**
- Singh YN. Kava: an overview. *J Ethnopharmacol* 1992;37:13-45. [View abstract.](#) **8415**
- Bilia AR, Gallori S, Vincieri FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. *Life Sci* 2002;70:2581-97. [View abstract.](#) **8417**
- Wooltorton E. Herbal kava: reports of liver toxicity. *CMAJ* 2002;166:777. [View abstract.](#) **8440**
- Boonen G, Pramanik A, Rigler R, Haberlein H. Evidence for specific interactions between kavain and human cortical neurons monitored by fluorescence correlation spectroscopy. *Planta Med* 2000;66:7-10. [View abstract.](#) **8740**
- Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. *Planta Med* 1997;63:548-549.. [View abstract.](#) **8742**
- Anon. Hepatic toxicity possibly associated with kava-containing products-United States, Germany, Switzerland, 1999-2002. *MMWR* 2002;1:1065-1067.. [View abstract.](#) **8743**
- Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. *Drug Metab Dispos* 2002;30:1153-7. [View abstract.](#) **9893**
- Cropley M, Cave Z, Ellis J, Middleton RW. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. *Phytother Res* 2002;16:23-7.. [View abstract.](#) **9920**
- Garner LF, Klinger JD. Some visual effects caused by the beverage kava. *J Ethnopharmacol* 1985;13:307-311.. [View abstract.](#) **9921**
- Denham A, McIntyre M, Whitehouse J. Kava--the unfolding story: report on a work-in-progress. *J Altern Complement Med* 2002;8:237-263.. [View abstract.](#) **9923**
- Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. *Prog Neuropsychopharmacol Biol Psychiatry* 1998;22:1105-20. [View abstract.](#) **9924**
- Singh YN. Effects of kava on neuromuscular transmission and muscle contractility. *J Ethnopharmacol* 1983;7:267-76.. [View abstract.](#) **10319**
- Logan JL, Ahmed J. Critical hypokalemic renal tubular acidosis due to Sjogren's syndrome: association with the purported immune stimulant echinacea. *Clin Rheumatol* 2003;22:158-9. [View abstract.](#) **11369**
- Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. *Phytomedicine* 2003;10:440-6. [View abstract.](#) **11370**
- Schmidt P, Boehncke WH. Delayed-type hypersensitivity reaction to kava-kava extract. *Contact Dermatitis* 2000;42:363-4. [View abstract.](#) **11371**
- Schulze J, Raasch W, Siegers CP. Toxicity of kava pyrones, drug safety and precautions--a case study. *Phytomedicine* 2003;10:68-73.. [View abstract.](#)

- Pittler MH, Ernst E. Kava extract for treating anxiety. *Cochrane Database Syst Rev* 2003;(1):CD003383. [View abstract](#). **11372**
- Cairney S, Maruff P, Clough AR, et al. Saccade and cognitive impairment associated with kava intoxication. *Hum Psychopharmacol* 2003;18:525-33. [View abstract](#). **11373**
- Moulds RF, Malani J. Kava: herbal panacea or liver poison? *Med J Aust* 2003;178:451-3. [View abstract](#). **11794**
- Gow PJ, Connelly NJ, Hill RL, et al. Fatal fulminant hepatic failure induced by a natural therapy containing kava. *Med J Aust* 2003;178:442-3. [View abstract](#). **11795**
- Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. *Rapid Commun Mass Spectrom* 2004;18:2273-81. [View abstract](#). **12479**
- Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Ther* 2005;77:415-26. [View abstract](#). **13536**
- Jacobs BP, Bent S, Tice JA, et al. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. *Medicine (Baltimore)* 2005;84:197-207. [View abstract](#). **15046**
- Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. *Int Clin Psychopharmacol* 2006;21:249-53. [View abstract](#). **15130**
- Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of *Piper methysticum* G. Forst (kava-kava) inhibit P-glycoprotein in vitro. *Drug Metab Dispos* 2005;33:1580-3. [View abstract](#). **15131**
- Gurley BJ, Swain A, Barone GW, et al. Effect of goldenseal (*Hydrastis canadensis*) and kava kava (*Piper methysticum*) supplementation on digoxin pharmacokinetics in humans. *Drug Metab Dispos* 2007;35:240-5. [View abstract](#). **15132**
- Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk-thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. *Mol Nutr Food Res* 2008;52:755-63. [View abstract](#). **16848**
- Li XZ, Ramzan I. Role of ethanol in kava hepatotoxicity. *Phytother Res* 2010;24:475-80. [View abstract](#). **17086**
- Bodkin R, Schneider S, Rekkerth D, et al. Rhabdomyolysis associated with kava ingestion. *Am J Emerg Med* 2012;30:635.e1-3. [View abstract](#). **18212**
- Donadio V, Bonsi P, Zele I, et al. Myoglobinuria after ingestion of extracts of guarana, Ginkgo biloba and kava. *Ginkgo biloba and kava. Neurol Sci* 2000;21:124. [View abstract](#). **18213**
- Connor KM, Davidson JR. A placebo-controlled study of Kava kava in generalized anxiety disorder. *Int Clin Psychopharmacol* 2002;17:185-8. [View abstract](#). **18313**
- Boerner RJ, Sommer H, Berger W, et al. Kava-Kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. *Phytomedicine* 2003;10 Suppl 4:38-49. [View abstract](#). **18314**
- 18315**

- Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonc kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. *Phytother Res* 2005;19:183-8. [View abstract](#). **18316**
- Sarris J, Kavanagh DJ, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. *Psychopharmacology* 2009;205:399-407. [View abstract](#). **18317**
- Gastpar M, Klimm HD. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial. *Phytomedicine* 2003;10:631-9. [View abstract](#). **18318**
- Cagnacci A, Arangino S, Renzi A, et al. Kava-Kava administration reduces anxiety in perimenopausal women. *Maturitas* 2003;44:103-9. [View abstract](#). **18319**
- Sarris J, Scholey A, Schweitzer I, et al. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. *Hum Psychopharmacol* 2012;27:262-9. [View abstract](#). **18320**
- Geier FP, Konstantinowicz T. Kava treatment in patients with anxiety. *Phytother Res* 2004;18:297-300. [View abstract](#). **18321**
- Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. *J Affect Disord* 2004;78:101-10. [View abstract](#). **28485**
- Hannam S, Murray M, Romani L, Tuicakau M, J Whitfield M. Kava dermatopathy in Fiji: an acquired ichthyosis? *Int J Dermatol* 2014;53(12):1490-4. [View abstract](#). **29643**
- Ketola RA, Viinamäki J, Rasanen I, Pelander A, Goebeler S. Fatal kavalactone intoxication by suicidal intravenous injection. *Forensic Sci Int* 2015;249:e7-e11. [View abstract](#). **29663**
- Sarris J, Stough C, Bousman CA, Wahid ZT, Murray G, Teschke R, Savage KM, Dowell A, Ng C, Schweitzer I. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. *J Clin Psychopharmacol* 2013;33(5):643-8. [View abstract](#). **29671**
- Sarris J, Stough C, Teschke R, Wahid ZT, Bousman CA, Murray G, Savage KM, Mouatt P, Ng C, Schweitzer I. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. *Phytother Res* 2013;27(11):1723-8. [View abstract](#). **29676**
- Teschke R, Sarris J, Schweitzer I. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. *Br J Clin Pharmacol* 2012;73(2):170-4. [View abstract](#). **30020**
- Meolie, A. L., Rosen, C., Kristo, D., Kohrman, M., Gooneratne, N., Aguillard, R. N., Fayle, R., Troell, R., Townsend, D., Claman, D., Hoban, T., and Mahowald, M. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. *J Clin.Sleep Med* 4-15-2005;1(2):173-187. [View abstract](#). **32187**
- Lakhan, S. E. and Vieira, K. F. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. *Nutr J* 2010;9:42. [View abstract](#). **35917**
- Kelley, K. W. and Carroll, D. G. Evaluating the evidence for over-the-counter alternatives for relief of hot flashes in menopausal women. *J.Am.Pharm.Assoc.(2003.)* 2010;50(5):e106-e115. [View abstract](#). **57228**

- Scherer, J. Kava-kava extract in anxiety disorders: an outpatient observational study. *Adv. Ther.* 1998;15(4):261-269. [View abstract](#). **57229**
- De Leo, V, La Marca, A., Lanzetta, D., Palazzi, S., Torricelli, M., Facchini, C., and Morgante, G. [Assessment of the association of Kava-Kava extract and hormone replacement therapy in the treatment of postmenopause anxiety]. *Minerva Ginecol.* 2000;52(6):263-267. [View abstract](#). **57230**
- Neuhaus, W., Ghaemi, Y., Schmidt, T., and Lehmann, E. [Treatment of perioperative anxiety in suspected breast carcinoma with a phytogetic tranquilizer]. *Zentralbl. Gynakol.* 2000;122(11):561-565. [View abstract](#). **57231**
- Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. *Phytother Res* 2001;15:549-551. [View abstract](#). **57232**
- Kraft, M., Spahn, T. W., Menzel, J., Senninger, N., Dietl, K. H., Herbst, H., Domschke, W., and Lerch, M. M. [Fulminant liver failure after administration of the herbal antidepressant Kava-Kava]. *Dtsch Med Wochenschr* 9-7-2001;126(36):970-972. [View abstract](#). **57233**
- Boerner, R. J. Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia. *Phytother Res* 2001;15(7):646-647. [View abstract](#). **57234**
- Watkins, L. L., Connor, K. M., and Davidson, J. R. Effect of kava extract on vagal cardiac control in generalized anxiety disorder: preliminary findings. *J Psychopharmacol.* 2001;15(4):283-286. [View abstract](#). **57239**
- Bujanda, L., Palacios, A., Silvarino, R., Sanchez, A., and Munoz, C. [Kava-induced acute icteric hepatitis]. *Gastroenterol. Hepatol.* 2002;25(6):434-435. [View abstract](#). **57240**
- Pittler, M. H. and Ernst, E. Kava extract for treating anxiety. *Cochrane Database. Syst Rev* 2002;(2):CD003383. [View abstract](#). **57241**
- Parkman, C. A. Another FDA warning: Kava supplements. *Case. Manager.* 2002;13(4):26-28. [View abstract](#). **57243**
- Cairney, S., Maruff, P., and Clough, A. R. The neurobehavioural effects of kava. *Aust. N.Z. J Psychiatry* 2002;36(5):657-662. [View abstract](#). **57245**
- Ernst, E. [Recall of the herbal anxiolytic kava. Underestimation of its value or overestimation of its risks?]. *MMW. Fortschr. Med* 10-10-2002;144(41):40. [View abstract](#). **57249**
- Cairney, S., Clough, A. R., Maruff, P., Collie, A., Currie, B. J., and Currie, J. Saccade and cognitive function in chronic kava users. *Neuropsychopharmacology* 2003;28(2):389-396. [View abstract](#). **57250**
- Feltenstein, M. W., Lambdin, L. C., Ganzera, M., Ranjith, H., Dharmaratne, W., Nanayakkara, N. P., Khan, I. A., and Sufka, K. J. Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social-separation-stress procedure. *Phytother Res* 2003;17(3):210-216. [View abstract](#). **57251**
- Currie, B. J. and Clough, A. R. Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use? *Med J Aust.* 5-5-2003;178(9):421-422. [View abstract](#). **57252**
- Humberston, C. L., Akhtar, J., and Krenzelok, E. P. Acute hepatitis induced by kava kava. *J Toxicol. Clin Toxicol.* 2003;41(2):109-113. [View abstract](#). **57253**
- Schmidt, M. Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory. *J Altern Complement Med* 2003;9(2):183-187. [View abstract](#).

- 57254**
- Stickel, F., Baumuller, H. M., Seitz, K., Vasilakis, D., Seitz, G., Seitz, H. K., and Schuppan, D. Hepatitis induced by Kava (*Piper methysticum* rhizoma). *J Hepatol.* 2003;39(1):62-67. [View abstract.](#)
- 57255**
- Garrett, K. M., Basmadjian, G., Khan, I. A., Schaneberg, B. T., and Seale, T. W. Extracts of kava (*Piper methysticum*) induce acute anxiolytic-like behavioral changes in mice. *Psychopharmacology (Berl)* 2003;170(1):33-41. [View abstract.](#)
- 57259**
- Kava: first suspended, now prohibited. *Prescrire.Int* 2003;12(66):142. [View abstract.](#)
- 57261**
- HAMILTON, M. The assessment of anxiety states by rating. *Br.J.Med.Psychol.* 1959;32(1):50-55. [View abstract.](#)
- 57262**
- Whitton, P. A., Lau, A., Salisbury, A., Whitehouse, J., and Evans, C. S. Kava lactones and the kava-kava controversy. *Phytochemistry* 2003;64(3):673-679. [View abstract.](#)
- 57264**
- Mills, E., Singh, R., Ross, C., Ernst, E., and Ray, J. G. Sale of kava extract in some health food stores. *CMAJ.* 11-25-2003;169(11):1158-1159. [View abstract.](#)
- 57265**
- Boon, H. S. and Wong, A. H. Kava: a test case for Canada's new approach to natural health products. *CMAJ.* 11-25-2003;169(11):1163-1164. [View abstract.](#)
- 57270**
- Thompson, R., Ruch, W., and Hasenohrl, R. U. Enhanced cognitive performance and cheerful mood by standardized extracts of *Piper methysticum* (Kava-kava). *Hum.Psychopharmacol.* 2004;19(4):243-250. [View abstract.](#)
- 57274**
- Jorm, A. F., Christensen, H., Griffiths, K. M., Parslow, R. A., Rodgers, B., and Blewitt, K. A. Effectiveness of complementary and self-help treatments for anxiety disorders. *Med J Aust* 2004;181(7 Suppl):S29-S46. [View abstract.](#)
- 57275**
- Boerner, R. J. and Klement, S. Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490. *Wien.Med Wochenschr.* 2004;154(21-22):508-510. [View abstract.](#)
- 57276**
- Foo, H. and Lemon, J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. *Drug Alcohol Rev.* 1997;16(2):147-155. [View abstract.](#)
- 57278**
- Ernst, E. Herbal remedies for anxiety - a systematic review of controlled clinical trials. *Phytomedicine* 2006;13(3):205-208. [View abstract.](#)
- 57279**
- Folmer, F., Blasius, R., Morceau, F., Tabudravu, J., Dicato, M., Jaspars, M., and Diederich, M. Inhibition of TNFalpha-induced activation of nuclear factor kappaB by kava (*Piper methysticum*) derivatives. *Biochem Pharmacol* 4-14-2006;71(8):1206-1218. [View abstract.](#)
- 57281**
- Musch, E., Chrissafidou, A., and Malek, M. [Acute hepatitis due to kava-kava and St John's Wort: an immune-mediated mechanism?]. *Dtsch Med Wochenschr.* 5-26-2006;131(21):1214-1217. [View abstract.](#)
- 57282**
- Prescott, J., Jamieson, D., Emdur, N., and Duffield, P. Acute effects of kava on measures of cognitive performance, physiological function and mood. *Drug Alcohol Rev.* 1993;12(1):49-57. [View abstract.](#)
- 57289**
- Geller, S. E. and Studee, L. Botanical and dietary supplements for mood and anxiety in menopausal women. *Menopause.* 2007;14(3 Pt 1):541-549. [View abstract.](#)
- 57290**

- Matthias, A., Blanchfield, J. T., Penman, K. G., Bone, K. M., Toth, I., and Lehmann, R. P. Permeability studies of Kavalactones using a Caco-2 cell monolayer model. *J Clin Pharm Ther* 2007;32(3):233-239. [View abstract](#). **57292**
- Zhou, S. F., Xue, C. C., Yu, X. Q., and Wang, G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. *Curr Drug Metab* 2007;8(6):526-553. [View abstract](#). **57293**
- Holm, E., Staedt, U., Heep, J., Kortsik, C., Behne, F., Kaske, A., and Mennicke, I. [The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness- rhythm in animals]. *Arzneimittelforschung*. 1991;41(7):673-683. [View abstract](#). **57294**
- van der Watt, G., Laugharne, J., and Janca, A. Complementary and alternative medicine in the treatment of anxiety and depression. *Curr Opin Psychiatry* 2008;21(1):37-42. [View abstract](#). **57295**
- Sarris, J., Kavanagh, D. J., Deed, G., and Bone, K. M. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. *Hum Psychopharmacol*. 2009;24(1):41-48. [View abstract](#). **57297**
- Christl, S. U., Seifert, A., and Seeler, D. Toxic hepatitis after consumption of traditional kava preparation. *J Travel Med*. 2009;16(1):55-56. [View abstract](#). **57298**
- Kinzler, E., Kromer, J., and Lehmann, E. [Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks]. *Arzneimittelforschung*. 1991;41(6):584-588. [View abstract](#). **57299**
- Sarris, J., Kavanagh, D. J., Adams, J., Bone, K., and Byrne, G. Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum. *Complement Ther Med*. 2009;17(3):176-178. [View abstract](#). **57300**
- Teschke, R., Genthner, A., and Wolff, A. Kava hepatotoxicity: comparison of aqueous, ethanolic, acetic kava extracts and kava-herbs mixtures. *J Ethnopharmacol*. 6-25-2009;123(3):378-384. [View abstract](#). **57301**
- Sarris, J. and Kavanagh, D. J. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. *J Altern Complement Med*. 2009;15(8):827-836. [View abstract](#). **57303**
- Sarris, J., Laporte, E., and Schweitzer, I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. *Aust N Z J Psychiatry* 2011;45(1):27-35. [View abstract](#). **57304**
- Faustino, T. T., Almeida, R. B., and Andreatini, R. [Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies]. *Rev Bras Psiquiatr*. 2010;32(4):429-436. [View abstract](#). **57305**
- Laporte, E., Sarris, J., Stough, C., and Scholey, A. Neurocognitive effects of kava (Piper methysticum): a systematic review. *Hum Psychopharmacol*. 2011;26(2):102-111. [View abstract](#). **57306**
- Sarris, J., Panossian, A., Schweitzer, I., Stough, C., and Scholey, A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. *Eur Neuropsychopharmacol*. 2011;21(12):841-860. [View abstract](#). **57307**
- Lindenberg, D. and Pitule-Schodel, H. [D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness]. *Fortschr Med*. 1-20-1990;108(2):49-53. [View abstract](#). **57310**
- Lehmann, E., Klieser, E., Klimke, A., Krach, H., and Spatz, R. The efficacy of Cavain in patients suffering from anxiety. *Pharmacopsychiatry* 1989;22(6):258-262. [View abstract](#).

- Duffield, A. M., Jamieson, D. D., Lidgard, R. O., Duffield, P. H., and Bourne, D. J. Identification of some human urinary metabolites of the intoxicating beverage kava. *J Chromatogr.* 7-28-1989;475:273-281. [View abstract](#). **57312**
- Cawte, J. Parameters of kava used as a challenge to alcohol. *Aust.N.Z.J Psychiatry* 1986;20(1):70-76. [View abstract](#). **57313**
- Pfeiffer, C. C., Murphree, H. B., and Goldstein, L. Effect of kava in normal subjects and patients. *Psychopharmacol Bull* 1967;4(3):12. [View abstract](#). **57315**
- Rasmussen, A. K., Scheline, R. R., Solheim, E., and Hansel, R. Metabolism of some kava pyrones in the rat. *Xenobiotica* 1979;9(1):1-16. [View abstract](#). **57318**
- Gleitz, J., Beile, A., and Peters, T. (+/-)-kavain inhibits the veratridine- and KCl-induced increase in intracellular Ca²⁺ and glutamate-release of rat cerebrocortical synaptosomes. *Neuropharmacology* 1996;35(2):179-186. [View abstract](#). **57320**
- Gleitz, J., Friese, J., Beile, A., Ameri, A., and Peters, T. Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na⁺ channel receptor sites. *Eur.J Pharmacol* 11-7-1996;315(1):89-97. [View abstract](#). **57322**
- Magura, E. I., Kopanitsa, M. V., Gleitz, J., Peters, T., and Krishtal, O. A. Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated Na⁽⁺⁾-channels in rat CA1 hippocampal neurons. *Neuroscience* 1997;81(2):345-351. [View abstract](#). **57324**
- Boonen, G., Ferger, B., Kuschinsky, K., and Haberlein, H. In vivo effects of the kavapyrones (+)-dihydromethysticin and (+/-)-kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. *Planta Med* 1998;64(6):507-510. [View abstract](#). **57326**
- Langosch, J. M., Normann, C., Schirrmacher, K., Berger, M., and Walden, J. The influence of (+/-)-kavain on population spikes and long-term potentiation in guinea pig hippocampal slices. *Comp Biochem.Physiol A Mol.Integr.Physiol* 1998;120(3):545-549. [View abstract](#). **57327**
- Woelk H, Kapoula O, Lehl S, and et al. [Treatment of patients suffering from anxiety- double-blind study: kava special extract versus benzodiazepines]. *Z Allg Med* 1993;69:271-277. **57330**
- Stafford N. Germany may ban kava kava herbal supplement, Reuter's News Service Germany (November 19, 2001). **57331**
- Gessner B and Cnota P. Extract of the kava-kava rhizome in comparison with diazepam and placebo. *Z Phytother* 1994;15(1):30-37. **57332**
- Johnson D, Frauendorf A, Stecker K, and et al. Neurophysiological active profile and tolerance of kava extract WS 1490, A pilot study with randomized evaluation. *TW Neurolgie Psychiatrie* 1991;5(6):349-354. **57333**
- Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Letter to health care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury (document issued March 25, 2002), contact information for FDA Medwatch program: 1-800-332-1088. **57334**
- Izzo AA and Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. *Drugs* 2001;61(15):2163-2175. **57335**
- 57337**

- Stoller, R. Reports of hepatotoxicity with kava. Proceedings of the 24th Annual Meeting of Representatives of National Centres Participating in the WHO Drug Monitoring Programme, Dunedin, New Zealand 2008; **57338**
- Center for Food Safety and Applied Nutrition (US Food and Drug Administration). Kava-containing dietary supplements may be associated with severe liver injury (document issued March 25, 2002). **57339**
- Mittmann, U., Schmidt, M., and Vrstayakova, J. Akut-anxiolytische wirksamkeit von Kava-Spissum-Spezialextrakt studie. Journal Pharmakoogie und Therapie 2000;9(4):99-108. **57340**
- Meyer HG. Pharmakologie der wirksamen prinzipien de kawarhizoms (Piper methysticum Forst.). Arch Int Pharmacodyn Ther 1962;138:505-536. **57346**
- Chanwai, L. G. Kava toxicity. Emergency Medicine 2002;12:142-145. **57348**
- Saletu B, Grünberger J, Linzmayer L, and et al. EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain-a kava plant derivative. Hum Psychopharm 1989;4:169-190. **57349**
- Leung, N. Acute urinary retention secondary to kava ingestion. Emerg Med Australas 2004;16(1):94. **57354**
- Singh Y and Blumenthal M. Kava: an overview. Distribution, mythology, botany, culture, chemistry and pharmacology of the South Pacific's most revered herb. HerbalGram 1997;39(Suppl 1):34-56. **57362**
- Ma, Y., Sachdeva, K., Liu, J., Ford, M., Yang, D., Khan, I. A., Chichester, C. O., and Yan, B. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab Dispos 2004;32(11):1317-1324. **57365**
- Walden J, von Wegerer J, Winter U, and et al. Actions of kavain and dihydromethysticin on ipsapirone-induced field potential changes in the hippocampus. Human Psychopharm 1997;12:265-270. **57366**
- Gleitz J, Gottner N, Ameri A, and et al. Kavain inhibits non-stereospecifically veratridine-activated Na **57367**
- Emser W and Bartylla K. Improvement of sleep quality. Effect of kava extract WS 1490 on the sleep pattern in healthy subjects. Neurologie/Psychiatrie 1991;5(11):636-642. **57368**
- Buckley, J. P., Furgiuele, A. R., and O'Hara, M. J. Pharmacology of kava. Ethnopharm Search Psych Drugs 1967;1:141-151. **57369**
- Furgiuele AR, Kinnard WJ, Aceto MD, and et al. Central activity of aqueous extracts of Piper methysticum (kava). J Pharm Sci 1965;54:247-252. **57370**
- Assessment of the Risk of Hepatotoxicity with Kava Products. 2000; **57371**
- Bhate H, Gerster G, and Gracza E. Orale Prämedikation mit Zubereitungen aus Piper methysticum bei operativen Eingriffen in Epiduralanästhesie. Erfahrungsheilkunde 1989;6:339-345. **57372**
- Lehmann E, Kinzler E, and Friedemann J. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - a double-blind placebo-controlled study of four weeks treatment. Phytomedicine 1996;3(2):113-119. **57373**

- Malsch U and Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. *Psychopharm* 2001;157(3):277-283. **57374**
- Russell P, Bakker D, and Singh N. The effects of kava on alerting and speed of access of information from long-term memory. *Bull Psychonom Soc* 1987;25:236-237. **57375**
- Food and Drug Administration. Consumer advisory: kava-containing dietary supplements may be associated with severe liver injury. FDA Center for Food Safety and Nutrition. 2002;1. **88532**
- Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. *Liver Int* 2010;30(9):1270-9. [View abstract](#). **88593**
- Toohy TP, Lu BY, Wada C. Toxic effects of psychotropics related to possible p450 enzyme inhibition by kava:report of 2 cases. *Prim Care Companion CNS Disord* 2013;15(5). [View abstract](#). **90885**
- Teschke R, Lebot V. Proposal for a Kava Quality Standardization Code. *Food Chem Toxicol* 2011;49(10):2503-16. [View abstract](#). **91593**
- Ostermayer D. News: Kava, Popular as Alcohol Alternative, May Cause Toxicity. *Emerg Med News*. 2016;38(1B). **91594**
- Kuchta K, Schmidt M, Nahrstedt A. German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (*Piper methysticum*) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics. *Planta Med*. 2015;81(18):1647-53. [View abstract](#). **91615**
- Schmidt M. German Court Ruling Reverses Kava Ban; German Regulatory Authority Appeals Decision. *HerbalEGram*. 2014;11(7).